Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:alsoKnownAs |
gptkb:Durvalumab
|
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:non-small_cell_lung_cancer
gptkb:urothelial_carcinoma |
| gptkbp:ATCCode |
L01FF03
|
| gptkbp:bindingTarget |
gptkb:programmed_death-ligand_1
|
| gptkbp:CASNumber |
1428935-60-7
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:drugClass |
immunotherapy
antineoplastic agent |
| gptkbp:EMAApprovalYear |
2018
|
| https://www.w3.org/2000/01/rdf-schema#label |
MEDI4736
|
| gptkbp:macromoleculeType |
gptkb:IgG1_kappa
|
| gptkbp:mechanismOfAction |
immunotherapy
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
diarrhea
fatigue rash pneumonitis immune-mediated hepatitis |
| gptkbp:target |
PD-L1
|
| gptkbp:UNII |
6Z5F2A6VNP
|
| gptkbp:usedFor |
immunotherapy
|
| gptkbp:bfsParent |
gptkb:Durvalumab
|
| gptkbp:bfsLayer |
6
|